Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.

about

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.

P2860

Q26770716-C569A4E1-8C85-4DAD-9882-B098D385816F Q38664909-E5739FA9-0F61-43DD-B657-3BB1219C7885

P2860

Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.

Item

http://www.wikidata.org/entity/Q38099028

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Hematopoietic progenitor cells ...... refractory Hodgkin's lymphoma.

@en

type

Item

label

Hematopoietic progenitor cells ...... refractory Hodgkin's lymphoma.

@en

prefLabel

Hematopoietic progenitor cells ...... refractory Hodgkin's lymphoma.

@en

P1476

Hematopoietic progenitor cells ...... refractory Hodgkin's lymphoma.

@en

P2093

Giuseppe Console

http://www.w3.org/2001/XMLSchema#string

Giuseppe Irrera

http://www.w3.org/2001/XMLSchema#string

Giuseppe Messina

http://www.w3.org/2001/XMLSchema#string

Massimo Martino

http://www.w3.org/2001/XMLSchema#string

Roberta Fedele

http://www.w3.org/2001/XMLSchema#string

Tiziana Moscato

http://www.w3.org/2001/XMLSchema#string

P2860

Standard therapy of advanced Hodgkin lymphoma

The EBMT activity survey: 1990-2010

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

P304

1013-1027

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.779250

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23586758

http://www.w3.org/2001/XMLSchema#string

Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.

about

P2860

P2860

Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698